Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
kymr · stock forecast · 26 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 26 Wall Street analysts in the past 3 months
Buy
26 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$134
Consensus
$117
+58.7% upside
Low
$97.00
Median: $119 · Last Close: $73.95
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$117.38
58.7% upside
High Target
$134
81.2%
Low Target
$97
31.2%
Current Price
$73.95
as of today
Based on analyst price targets, the KYMR stock price prediction for the next 12 months ranges from $97 to $134. The consensus KYMR price forecast of $117.38 implies 58.7% upside from the current price of $73.95.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $70.25 | ↓ 5.00% |
1-day model range: $69.9–$70.61. Peak: $70.61 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · KYMR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-03 | UBS | Maintains | Buy→Buy |
| 2026-03-02 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2026-03-02 | Citigroup | Maintains | Buy→Buy |
| 2026-02-26 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-02-26 | BTIG | Maintains | Buy→Buy |
| 2026-02-03 | BTIG | Maintains | Buy→Buy |
| 2026-01-28 | Barclays | Maintains | Overweight→Overweight |
| 2026-01-15 | BTIG | Maintains | Buy→Buy |
| 2026-01-06 | Wolfe Research | Downgrade ↓ | Outperform→Peer Perform |
| 2025-12-22 | B. Riley Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Kymera Therapeutics, Inc. (KYMR) stock. Of the recent 117 rating actions, 6 were upgrades and 4 were downgrades. 26 analysts currently cover KYMR.
Analyst Recommendation Trends
KYMR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$80M
↑ 103.3% YoY
Revenue Next Year
$39M
↓ 50.7% YoY
EPS This Year
$-3.50
EPS Next Year
$-4.30
↑ 22.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast KYMR EPS of $-3.50 for the current fiscal year, based on estimates from 17 analysts. The KYMR revenue forecast is $80M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KYMR stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KYMR price target is $117.38 (+58.7% upside), with an analyst consensus of Buy.
The KYMR short-term stock prediction for tomorrow is $70.25 (-5.00%).
Kymera Therapeutics, Inc. trades on NASDAQ under the ticker KYMR. The KYMR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
KYMR forecast · 8 questionsAccording to 26 Wall Street analysts, the average 12-month KYMR price target is $117.38, with a high forecast of $134.00 and a low of $97.00. The median price target is shown in the chart above when available. This implies +58.7% potential upside from the current price of $73.95.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.